These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 22400811

  • 21. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
    Chen LM, Liang YJ, Ruan JW, Ding Y, Wang XW, Shi Z, Gu LQ, Yang XP, Fu LW.
    J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
    [Abstract] [Full Text] [Related]

  • 22. Reversal of cancer multidrug resistance by green tea polyphenols.
    Mei Y, Qian F, Wei D, Liu J.
    J Pharm Pharmacol; 2004 Oct; 56(10):1307-14. PubMed ID: 15482646
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts.
    Klement G, Huang P, Mayer B, Green SK, Man S, Bohlen P, Hicklin D, Kerbel RS.
    Clin Cancer Res; 2002 Jan; 8(1):221-32. PubMed ID: 11801563
    [Abstract] [Full Text] [Related]

  • 27. Drug resistance in chemotherapy for breast cancer.
    Saeki T, Tsuruo T, Sato W, Nishikawsa K.
    Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():84-9. PubMed ID: 16273361
    [Abstract] [Full Text] [Related]

  • 28. Apoptosis induction and modulation of P-glycoprotein mediated multidrug resistance by new macrocyclic lathyrane-type diterpenoids.
    Duarte N, Varga A, Cherepnev G, Radics R, Molnár J, Ferreira MJ.
    Bioorg Med Chem; 2007 Jan 01; 15(1):546-54. PubMed ID: 17035027
    [Abstract] [Full Text] [Related]

  • 29. Significant activity of ecdysteroids on the resistance to doxorubicin in mammalian cancer cells expressing the human ABCB1 transporter.
    Martins A, Tóth N, Ványolós A, Béni Z, Zupkó I, Molnár J, Báthori M, Hunyadi A.
    J Med Chem; 2012 Jun 14; 55(11):5034-43. PubMed ID: 22578055
    [Abstract] [Full Text] [Related]

  • 30. Potent reversal of multidrug resistance by ningalins and its use in drug combinations against human colon carcinoma xenograft in nude mice.
    Chou TC, Guan Y, Soenen DR, Danishefsky SJ, Boger DL.
    Cancer Chemother Pharmacol; 2005 Oct 14; 56(4):379-90. PubMed ID: 15875185
    [Abstract] [Full Text] [Related]

  • 31. Synthesis and evaluation of nitric oxide-releasing DDB derivatives as potential Pgp-mediated MDR reversal agents in MCF-7/Adr cells.
    Tang X, Gu X, Ai H, Wang G, Peng H, Lai Y, Zhang Y.
    Bioorg Med Chem Lett; 2012 Jan 15; 22(2):801-5. PubMed ID: 22209486
    [Abstract] [Full Text] [Related]

  • 32. Design and syntheses of permethyl ningalin B analogues: potent multidrug resistance (MDR) reversal agents of cancer cells.
    Zhang PY, Wong IL, Yan CS, Zhang XY, Jiang T, Chow LM, Wan SB.
    J Med Chem; 2010 Jul 22; 53(14):5108-20. PubMed ID: 20560605
    [Abstract] [Full Text] [Related]

  • 33. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U, Lynch J, Sato Y, Kashimoto S, Kajikawa F, Furutani Y, Silverman JA.
    Cancer Chemother Pharmacol; 2009 Jun 22; 64(1):53-65. PubMed ID: 18931998
    [Abstract] [Full Text] [Related]

  • 34. RS-33295-198: a novel, potent modulator of P-glycoprotein-mediated multidrug resistance.
    Slate DL, Bruno NA, Casey SM, Zutshi N, Garvin LJ, Wu H, Pfister JR.
    Anticancer Res; 1995 Jun 22; 15(3):811-4. PubMed ID: 7645963
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone.
    Lee FY, Smykla R, Johnston K, Menard K, McGlinchey K, Peterson RW, Wiebesiek A, Vite G, Fairchild CR, Kramer R.
    Cancer Chemother Pharmacol; 2009 Jan 22; 63(2):201-12. PubMed ID: 18350296
    [Abstract] [Full Text] [Related]

  • 37. Multidrug resistance reverting activity and antitumor profile of new phenothiazine derivatives.
    Bisi A, Meli M, Gobbi S, Rampa A, Tolomeo M, Dusonchet L.
    Bioorg Med Chem; 2008 Jul 01; 16(13):6474-82. PubMed ID: 18522868
    [Abstract] [Full Text] [Related]

  • 38. Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance.
    Fu L, Liang Y, Deng L, Ding Y, Chen L, Ye Y, Yang X, Pan Q.
    Cancer Chemother Pharmacol; 2004 Apr 01; 53(4):349-56. PubMed ID: 14666379
    [Abstract] [Full Text] [Related]

  • 39. Potentiation of the antitumor activity by a novel quinoline compound, MS-209, in multidrug-resistant solid tumor cell lines.
    Nakanishi O, Baba M, Saito A, Yamashita T, Sato W, Abe H, Fukazawa N, Suzuki T, Sato S, Naito M, Tsuruo T.
    Oncol Res; 1997 Apr 01; 9(2):61-9. PubMed ID: 9167187
    [Abstract] [Full Text] [Related]

  • 40. Structure-activity relationships of some taxoids as multidrug resistance modulator.
    Hasegawa T, Bai J, Zhang S, Wang J, Matsubara J, Kawakami J, Tomida A, Tsuruo T, Hirose K, Sakai J, Kikuchi M, Abe M, Ando M.
    Bioorg Med Chem Lett; 2007 Feb 15; 17(4):1122-6. PubMed ID: 17239597
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.